Loading...
The recommendation to prescribe ticagrelor over clopidogrel in dual antiplatelet therapy for patients with an acute coronary syndrome (ACS) largely derives from the randomized PLATO trial, in which ticagrelor was associated with lower relative risks for major adverse coronary events (MACE) and death (16% and 22%, respectively) but with higher relative risks for major bleeding and dyspnea (19% and 84%, respectively). Ticagrelor's benefits, however, were not seen in the North American cohort, which the authors later attributed to the higher aspirin dose commonly used in this region. The current investigators leveraged a Canadian population-based registry to determine the real-world comparative effectiveness of ticagrelor and clopidogrel in an…